Effect Of Thymosin On Cellular Immunity Of Patients With Stable COPD

Objective:To observe the effect of thymosin alpha 1 on the immune function of patients with stable chronic obstructive pulmonary disease(COPD)by evaluating the T cell subsets(CD4%,CD8% and CD4/CD8 ratios)in patients with stable chronic obstructive pulmonary disease(COPD),and to evaluate the clinical efficacy.Methods:A prospective,randomized controlled study was conducted.According to the inclusion and exclusion criteria,30 healthy subjects were selected as normal control group.60 patients with stable COPD were selected as case group.They were divided into two groups by random number table.The treatment group(COPD standard therapy plus thymosin alpha 1 adjuvant treatment)and the routine group(COPD standard treatment),each 30 cases.The routine group was given standardized treatment.The treatment group was given COPD standard treatment,supplemented by thymosin alpha 1,subcutaneous injection,2/ weeks,and 4 weeks as 1 courses.The cellular immunity indexes(CD4%,CD8%,CD4/CD8 ratio)were examined before,after treatment and 1 years after treatment.The lung function was measured before and after the treatment,and the ratio of forced expiratory breath to forced lung activity(FEV1%)was recorded for one second.The number of acute episodes before and after 1 years of treatment was recorded.Data were statistically analyzed by SPSS 21 statistical software,including t test,nonparametric test,chi square test and Spearman correlation analysis.When P<0.05 was used,there was statistical difference.Results: The ratio of CD4% and CD4/CD8 in the chronic obstructive pulmonary group was significantly lower than that in the healthy control group,and the CD8% increased,and there was a statistically significant difference(P<0.05).There was no statistical difference between the routine group before and after treatment(p>0.05).The treatment group was improved after treatment than before treatment(P<0.05).After treatment,the treatment group was better than the conventional group(P<0.05).After 1 years of reexamination,there was no statistical difference between the 1 years after treatment(p>0.05).There was no statistical difference between the conventional group and the treatment group after 1 years.There was no statistical difference between the treatment group and the conventional group(CD4% and CD8%)(p>0.05).The lung function of the slow Lung Group was lower than that of the healthy control group.The lung function in the conventional group was not statistically different after treatment for 1 years(P>0.05).The reexamination in the treatment group improved 1 years later than that before treatment(P<0.05),and the treatment group was improved compared with the conventional group(P<0.05).The number of acute episodes in the treatment group decreased after treatment(P<0.05),but there was no significant difference between the two groups before and after treatment(P<0.05),and the number of acute episodes in the treatment group was lower than that in the conventional group(P<0.05).Conclusion: there is a decline in cellular immune function in patients with chronic obstructive pulmonary disease,and the number of acute attacks and changes of lung function are associated with the immune state.The use of thymosin alpha 1 can quickly improve the cellular immune function in the short term.After stopping use thymosin alpha 1,The immune function will decrease in degree.Adjuvant therapy with thymosin alpha 1 regulate immuno therapy to improve the prognosis of patients with stable stage.